

Table S1. Leukemogenic driver mutations used for CHIP variant calling

Gene name	Reported mutations used for variant calling	Accession
ASXL1	Frameshift/nonsense/splice-site in exon 11-12	NM_015338
ASXL2	Frameshift/nonsense/splice-site in exon 11-12	NM_018263
BCOR	Frameshift/nonsense/splice-site	NM_001123385
BCORL1	Frameshift/nonsense/splice-site	NM_021946
BRAF	G464E, G464V, G466E, G466V, G469R, G469E, G469A, G469V, V471F, V472S, L485W, N581S, I582M, I592M, I592V, D594N, D594G, D594V, D594E, F595L, F595S, G596R, L597V, L597S, L597Q, L597R, A598V, V600M, V600L, V600K, V600R, V600E, V600A, V600G, V600D, K601E, K601N, R603*, W604R, W604G, S605G, S605F, S605N, G606E, G606A, G606V, H608R, H608L, G615R, S616P, S616F, L618S, L618W	NM_004333
BRCC3	Frameshift/nonsense/splice-site	NM_024332
CBL	RING finger missense p.381-421	NM_005188
CBLB	RING finger missense p.372-412	NM_170662
CEBPA	Frameshift/nonsense/splice-site	NM_004364
CREBBP	Frameshift/nonsense/splice-site, D1435E, R1446L, R1446H, R1446C, Y1450C, P1476R, Y1482H, H1487Y, W1502C, Y1503D, Y1503H, Y1503F, S1680del	NM_004380
CSF1R	L301F, L301S, Y969C, Y969N, Y969F, Y969H, Y969D	NM_005211
CSF3R	T615A, T618I, truncating c.741-791	NM_000760
CTCF	Frameshift/nonsense, R377C, R377H, P378A, P378L	NM_006565
CUX1	Frameshift/nonsense	NM_181552
DNMT3A	Frameshift/nonsense/splice-site, F290I, F290C, V296M, P307S, P307R, R326H, R326L, R326C, R326S, G332R, G332E, V339A, V339M, V339G, L344Q, L344P, R366P, R366H, R366G, A368T, A368V, R379H, R379C, I407T, I407N, I407S, F414L, F414S, F414C, A462V, K468R, C497G, C497Y, Q527H, Q527P, Y533C, S535F, C537G, C537R, G543A, G543S, G543C, L547H, L547P, L547F, M548I, M548K, G550R, W581R, W581G, W581C, R604Q, R604W, R635W, R635Q, S638F, G646V, G646E, L653W, L653F, I655N, V657A, V657M, R659H, Y660C, V665G, V665L, M674V, R676W, R676Q, G685R, G685E, G685A, D686Y, D686G, R688H, G699R, G699S, G699D, P700L, P700S, P700R, P700Q, P700T, P700A, D702N, D702Y, V704M, V704G, I705F, I705T, I705S, I705N, G707D, G707V, C710S, C710Y, S714C, V716D, V716F, V716L, N717S, N717I, P718L, R720H, R720G, K721R, K721T, Y724C, R729Q, R729W, R729G, F731C, F731L, F731Y, F731I, F732del, F732C, F732S, F732L, E733G, E733A, F734L, F734C, Y735C, Y735N, Y735S, R736H, R736C, R736P, L737H, L737V, L737F, L737R, A741V, P742P, P743R, P743L, R749C, R749L, R749H, R749G, F751L, F751C, F752del, F752C, F752L, F752I, F752V, W753G, W753C, W753R, L754P, L754R, L754H, F755S, F755I, F755L, M761I, M761V, G762C, V763I, S770L, S770W, S770P, R771Q, F772I, F772V, L773R, L773V, E774K, E774D, E774G, I780T, D781G, R792H, W795C, W795L, G796D, G796V, N797Y, N797H, N797S, P799S, P799R, P799H, R803S, R803W, P804L, P804S, K826R, S828N, K829R, T835M, N838D, K841Q, Q842E, P849L, D857N, W860R, E863D, F868S, G869S, G869V, M880V, S881R, S881I, R882H, R882P, R882C, R882G, A884P, A884V, Q886R, L889P, L889R, G890D, G890R, G890S, V895M, P896L, V897G, V897D, R899L, R899H, R899C, L901R, L901H, P904L, F909C, P904Q, A910P, C911R, C911Y	NM_022552

Kestenbaum et al, AJKD, "Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population"

EED	Frameshift/nonsense/splice-site, L240Q, I363M	NM_003797
EP300	Frameshift/nonsense/splice_site, VF1148_1149del, D1399N, D1399Y, P1452L, Y1467N, Y1467H, Y1467C, R1627W, A1629V	NM_001429
ETNK1	N244S, N244T, N244K	NM_018638
ETV6	Frameshift/nonsense/splice-site	NM_001987
EZH2	Frameshift/nonsense/splice-site, Q62R, N102S, F145S, F145C, F145Y, F145L, G159R, E164D, R202Q, K238E, E244K, R283Q, H292R, P488S, R497Q, R561H, T568I, K629E, Y641N, Y641H, Y641S, Y641C, Y641F, D659Y, D659G, V674M, A677G, A677V, R679C, R679H, R685C, R685H, A687V, N688I, N688K, H689Y, S690P, I708V, I708T, I708M, E720K, E740K	NM_001203247
FLT3	V579A, V592A, V592I, F594L, FY590-591GD, D835Y, D835H, D835E, del835	NM_004119
GATA1	Frameshift/nonsense/splice-site	NM_002049
GATA2	Frameshift/nonsense/splice-site, R293Q, N317H, A318T, A318V, A318G, G320D, L321P, L321F, L321V, Q328P, R330Q, R361L, L359V, A372T, R384G, R384K	NM_001145661
GATA3	Frameshift/nonsense/splice-site ZNF domain, R276W, R276Q, N286T, L348V,	NM_001002295
GNA13	I34T, G57S, S62F, M68K, Q134R, Y145F, L152F, E167D, Q169H, R264H, E273K, V322G, V362G, L371F	NM_006572
GNAS	R201S, R201C, R201H, R201L, Q227K, Q227R, Q227L, Q227H, R374C	NM_000516
GNB1	K57N, K57M, K57E, K57T, I80T, I80N	NM_002074
IDH1	R132C, R132G, R132H, R132L, R132P, R132V, V178I	NM_005896
IDH2	R140W, R140Q, R140L, R140G, R172W, R172G, R172K, R172T, R172M, R172N, R172S	NM_002168
IKZF1	Frameshift/nonsense	NM_006060
IKZF2	Frameshift/nonsense	NM_016260
IKZF3	Frameshift/nonsense	NM_012481
JAK1	T478A, T478S, V623A, A634D, L653F, R724H, R724Q, R724P, T782M, L783F	NM_002227
JAK2	N533D, N533Y, N533S, H538R, K539E, K539L, I540T, I540V, V617F, R683S, R683G, del/ins537-539L, del/ins538-539L, del/ins540-543MK, del/ins540-544MK, del/ins541-543K, del542-543, del543-544, ins11546-547	NM_004972
JAK3	M511T, M511I, A572V, A572T, A573V, R657Q, V715I, V715A	NM_000215
KDM6A	Frameshift/nonsense/splice-site, del419	NM_021140
KIT	ins503, V559A, V559D, V559G, V559I, V560D, V560A, V560G, V560E, del560, E561K, del579, P627L, P627T, R634W, K642E, K642Q, V654A, V654E, H697Y, H697D, E761D, K807R, D816H, D816Y, D816F, D816I, D816V, D816H, del551-559	NM_000222
KRAS	G12D, G12A, G12E, G12V, G13D, G13C, G13Y, G13F, G13R, G13A, G13V, G13E, V14I, T58I, G60D, G60A, G60V, Q61K, Q61E, Q61P, Q61R, Q61L, Q61H, K117E, K117N, A146T, A146P, A146V	NM_033360
LUC7L2	Frameshift/nonsense/splice-site	NM_016019
MLL	Frameshift/nonsense	NM_005933
MLL2	Frameshift/nonsense	NM_003482
MPL	S505G, S505N, S505C, L510P, del513, W515A, W515R, W515K, W515S, W515L, A519T, A519V, Y591D, W515-518KT	NM_005373

Kestenbaum et al, AJKD, "Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population"

NF1	Frameshift/nonsense	NM_000267
NPM1	Frameshift p.W288fs (insertion at c.859_860, 860_861, 862_863, 863_864)	NM_002520
NRAS	G12S, G12R, G12C, G12N, G12P, G12Y, G12D, G12A, G12V, G12E, G13S, G13R, G13C, G13N, G13P, G13Y, G13D, G13A, G13V, G13E, G60E, G60R, Q61R, Q61L, Q61K, Q61P, Q61H, Q61Q	NM_002524
PDS5B	Frameshift/nonsense/splice-site, R1292Q	NM_015032
PDSS2	Frameshift/nonsense	NM_020381
PHF6	Frameshift/nonsense/splice-site, A40D, M125I, S246Y, F263L, R274Q, C297Y, H302Y, H329L	NM_001015877
PHIP	Frameshift/nonsense/splice-site	NM_017934
PPM1D	Frameshift/nonsense, exon 5 or 6	NM_003620
PRPF40B	Frameshift/nonsense/splice-site, P15H, M58I, P405L, P562S,	NM_001031698
PRPF8	M1307I, C1594W, D1598Y, D1598N, D1598V	NM_006445
PTEN	Frameshift/nonsense/splice-site, D24G, R47G, F56V, L57W, H61R, K66N, Y68H, C71Y, F81C, Y88C, D92G, D92V, D92E, H93Y, H93D, H93Q, N94I, P95L, I101T, C105F, C105S, D107Y, L112V, H123Y, C124R, C124S, K125E, A126D, K128N, R130G, R130Q, R130L, G132D, I135V, I135K, C136R, C136F, K144Q, A151T, D153Y, D153N, Y155H, Y155C, R159K, R159S, R161K, R161I, G165R, G165E, S170N, S170I, R173C, Y174D, Y177C, H196Y, R234W, G251C, D252Y, F271S, D326G	NM_000314
PTPN11	G60V, G60R, G60A, D61Y, D61V, D61G, Y63C, E69K, E69G, E69D, E69Q, F71L, F71K, A72T, A72V, A72D, T73I, E76K, E76Q, E76M, E76A, E76G, E139G, E139D, N308D, N308T, N339S, P491L, S502P, S502A, S502L, G503V, G503G, G503A, G503E, Q506P, T507A, T507K	NM_002834
RAD21	Frameshift/nonsense/splice-site, R65Q, H208R, Q474R	NM_006265
RUNX1	Frameshift/nonsense/splice-site, S73F, H78Q, H78L, R80C, R80P, R80H, L85Q, P86L, P86H, S114L, D133Y, L134P, R135G, R135K, R135S, R139Q, R142S, A165V, R174Q, R177L, R177Q, A224T, D171G, D171V, D171N, R205W, R223C	NM_001001890
SETBP1	D868N, D868T, S869N, G870S, I871T, D880N, D880Q	NM_015559
SETD2	Frameshift/nonsense, V1190M	NM_014159
SETDB1	Frameshift/nonsense, K715E	NM_001145415
SF1	Frameshift/nonsense/splice-site, T454M, Y476C, A508G	NM_004630
SF3A1	Frameshift/nonsense/splice-site, A57S, M117I, K166T, Y271C	NM_005877
SF3B1	G347V, R387W, R387Q, E592K, E622D, Y623C, R625L, R625C, R625G, H662Q, H662D, T663I, K666N, K666T, K666E, K666R, K700E, V701F, A708T, G740R, G740E, A744P, D781G, E783K, R831Q, L833F, E862K, R957Q	NM_012433
SRSF2	Y44H, P95H, P95L, P95T, P95R, P95A, P107H, P95fs	NM_003016
SMC1A	K190T, R586W, M689V, R807H, R1090H, R1090C	NM_006306
SMC3	Frameshift/nonsense, R155I, Q367E, D392V, K571R, R661P, G662C	NM_005445
STAG1	Frameshift/nonsense/splice-site, H1085Y	NM_005862
STAG2	Frameshift/nonsense/splice-site	NM_006603
SUZ12	Frameshift/nonsense	NM_015355
TET2	Frameshift/nonsense/splice-site, missense mutations in catalytic domains (p.1104-1481 and 1843-2002)	NM_001127208

Kestenbaum et al, AJKD, "Clonal Hematopoiesis of Indeterminate Potential and Kidney Function Decline in the General Population"

TP53	Frameshift/nonsense/splice-site, S46F, G105C, G105R, G105D, G108S, G108C, R110L, R110C, T118A, T118R, T118I, S127F, S127Y, L130V, L130F, K132Q, K132E, K132W, K132R, K132M, K132N, F134V, F134L, F134S, C135W, C135S, C135F, C135G, C135Y, Q136K, Q136E, Q136P, Q136R, Q136L, Q136H, A138P, A138V, A138A, A138T, T140I, C141R, C141G, C141A, C141Y, C141S, C141F, C141W, V143M, V143A, V143E, L145Q, W146C, W146L, L145R, V147G, P151T, P151A, P151S, P151H, P151R, P152S, P152R, P152L, T155P, T155A, V157F, R158H, R158L, A159V, A159P, A159S, A159D, A161T, A161D, Y163N, Y163H, Y163D, Y163S, Y163C, K164E, K164M, K164N, K164P, H168Y, H168P, H168R, H168L, H168Q, M169I, M169T, M169V, E171K, E171Q, E171G, E171A, E171V, E171D, V172D, V173M, V173L, V173G, R174W, R175G, R175C, R175H, C176R, C176G, C176Y, C176F, C176S, P177R, P177R, P177L, H178D, H178P, H178Q, H179Y, H179R, H179Q, R181C, R181Y, D186G, G187S, P190L, P190T, H193N, H193P, H193L, H193R, L194F, L194R, I195F, I195N, I195T, R196P, V197L, G199V, Y205N, Y205C, Y205H, D208V, R213Q, R213P, R213L, R213Q, H214D, H214R, S215G, S215I, S215R, V216M, V217G, Y220N, Y220H, Y220S, Y220C, E224D, I232F, I232N, I232T, I232S, Y234N, Y234H, Y234S, Y234C, Y236N, Y236H, Y236C, M237V, M237K, M237I, C238R, C238G, C238Y, C238W, N239T, N239S, S241Y, S241C, S241F, C242G, C242Y, C242S, C242F, G244S, G244C, G244D, G245S, G245R, G245C, G245D, G245A, G245V, G245S, M246V, M246K, M246R, M246I, N247I, R248W, R248G, R248Q, R249G, R249W, R249T, R249M, P250L, I251N, L252P, I254S, I255F, I255N, I255S, L257Q, L257P, E258K, E258Q, D259Y, S261T, G262D, G262V, L265P, G266R, G266E, G266V, R267W, R267Q, R267P, E271K, V272M, V272L, R273S, R273G, R273C, R273H, R273P, R273L, V274F, V274D, V274A, V274G, V274L, C275Y, C275S, C275F, A276P, C277F, C277Y, P278T, P278A, P278S, P278H, P278R, P278L, G279E, R280G, R280K, R280T, R280I, R280S, D281N, D281H, D281Y, D281G, D281E, R282G, R282W, R282Q, R282P, E285K, E285V, E286G, E286V, E286K, K320N, L330R, G334V, R337C, R337L, A347T, L348F, T377P	NM_001126112
U2AF1	D14G, S34F, S34Y, R35L, R156H, R156Q, Q157R, Q157P	NM_006758
U2AF2	R18W, Q143L, M144I, L187V, Q190L	NM_007279
WT1	Frameshift/nonsense/splice-site	NM_024426
ZRSR2	Frameshift/nonsense, R126P, E133G, C181F, H191Y, I202N, F239V, F239Y, N261Y, C280R, C302R, C326R, H330R, N382K	NM_005089

Table S2. Associations of Clonal Hematopoiesis with 40% Decline in eGFR

	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	Number of events	Incidence per 100 person-years	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)
ARIC	Yes	584	3 (3,4)	9 (8,22)	81	1.20	1.26 (1.00,1.59)	1.21 (0.96,1.52)
	No	5,991	3 (3,4)	9 (8,23)	757	1.03	<i>reference</i>	<i>reference</i>
CHS	Yes	240	3 (2,3)	7 (3,7)	12	0.53	0.84 (0.46, 1.52)	0.84 (0.46, 1.54)
	No	1,461	3 (2,3)	7 (4,7)	103	0.70	<i>reference</i>	<i>reference</i>
MESA	Yes	178	4 (4, 4)	9 (9, 10)	4	0.26	0.41 (0.15, 1.09)	0.32 (0.12, 0.89)
	No	3,550	4 (4, 4)	9 (9, 10)	179	0.57	<i>reference</i>	<i>reference</i>
Meta-Analysis	Yes	1,002	3 (3,4)	8 (7, 14)	97	0.87	0.98 (0.60, 1.65)	0.79 (0.40, 1.56)
	No	11,002	3 (3,4)	8 (7, 15)	1039	0.84	<i>reference</i>	<i>reference</i>
							p = 0.765	p = 0.494
<p>ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate.*Adjusted for age, age-squared, sex, baseline eGFR, diabetes and log-urine albumin to creatinine ratio (where available at baseline).</p>								

Table S3. Associations of Clonal Hematopoiesis with Incident eGFR < 60 ml/min/1.73m²

	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	Number of events	Incidence per 100 person-years	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)
ARIC	Yes	573	3 (3,4)	9 (8,22)	96	1.46	1.27 (1.03,1.57)	1.15 (0.93,1.42)
	No	5,931	3 (3,4)	9 (8,23)	881	1.21	<i>reference</i>	<i>reference</i>
CHS	Yes	197	3 (2,3)	7 (4,8)	55	3.62	1.13 (0.85, 1.51)	1.05 (0.79, 1.41)
	No	1,255	3 (2,3)	7 (4,13)	326	3.25	<i>reference</i>	<i>reference</i>
MESA	Yes	151	4 (4, 4)	9 (9, 10)	42	3.38	1.09 (0.80, 1.50)	0.86 (0.63, 1.18)
	No	3,225	4 (4, 4)	9 (9, 10)	794	2.94	<i>reference</i>	<i>reference</i>
Meta-Analysis	Yes	921	3 (3,4)	8 (7, 14)	193	2.49	1.19 (1.02, 1.38)	1.05 (0.89, 1.23)
	No	10,411	3 (3,4)	8 (7, 15)	2,001	2.22	<i>reference</i>	<i>reference</i>
							p = 0.023	p = 0.592
<p>ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate.*Adjusted for age, age-squared, sex, baseline eGFR, diabetes and log-urine albumin to creatinine ratio (where available at baseline).</p>								

Table S4. Associations of DNMT3A clonal hematopoiesis with 30% decline in eGFR and longitudinal change in eGFR

Study	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	30% decline in eGFR				Percent eGFR decline per year	
					Number of events	Incidence per 100 p-y	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)	Mean (SD)	Adjusted† difference (95% CI)
ARIC	Yes	253	3 (2,3)	9 (3,9)	57	2.10	1.20 (0.92, 1.57)	1.13 (0.86, 1.47)	-2.37 (3.32)	-0.23 (-0.62, 0.15)
	No	6322	3 (2,3)	8 (3,9)	1478	1.96	<i>reference</i>	<i>reference</i>	-2.03 (2.80)	<i>reference</i>
CHS	Yes	136	3 (2,3)	7 (3,7)	19	1.64	1.11 (0.70, 1.77)	1.06 (0.66, 1.69)	-0.69 (4.86)	0.01 (-0.62, 0.63)
	No	1565	3 (2,3)	7 (4,8)	257	1.52	<i>reference</i>	<i>reference</i>	-0.94 (3.81)	<i>reference</i>
MESA	Yes	110	4 (4, 4)	9 (9, 10)	14	1.46	0.99 (0.58, 1.68)	0.83 (0.49, 1.42)	-1.64 (2.37)	0.26 (-0.21, 0.72)
	No	3,618	4 (4, 4)	9 (9, 10)	441	1.39	<i>reference</i>	<i>reference</i>	-1.70 (2.44)	<i>reference</i>
Meta-Analysis	Yes	499	3 (2,3)	8 (8, 8)	90	1.83	1.14 (0.93, 1.42)	1.06 (0.86, 1.31)	-1.72 (1.79)	-0.01 (-0.34, 0.32)
	No	11,505	3 (2,3)	8 (8, 8)	2,176	1.71	<i>reference</i>	<i>reference</i>	-1.67 (1.66)	<i>reference</i>
							p = 0.212	p = 0.585		p = 0.954

ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate. *Adjusted for age, age-squared, sex, baseline eGFR, diabetes, and log-urine albumin to creatinine ratio (where available at baseline). †Adjusted for age, age-squared, sex, diabetes and log-urine albumin to creatinine ratio (where available at baseline)

Table S5. Associations of non-DNMT3A clonal hematopoiesis with 30% decline in eGFR and longitudinal change in eGFR

Study	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	30% decline in eGFR				Percent eGFR decline per year	
					Number of events	Incidence per 100 p-y	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)	Mean (SD)	Adjusted† difference (95% CI)
ARIC	Yes	331	3 (2,3)	9 (3,9)	86	2.27	1.23 (0.99, 1.53)	1.24 (0.99, 1.54)	-2.26 (2.89)	-0.24 (-0.58, 0.09)
	No	6244	3 (2,3)	9 (3,9)	1449	1.95	<i>reference</i>	<i>reference</i>	-2.03 (2.82)	<i>reference</i>
CHS	Yes	104	3 (2,3)	7 (3,7)	21	2.34	1.81 (1.10, 2.98)	1.84 (1.05, 3.20)	-1.10 (3.83)	-0.04 (-0.75, 0.68)
	No	1597	3 (2,3)	7 (4,8)	235	1.57	<i>reference</i>	<i>reference</i>	-0.84 (4.01)	<i>reference</i>
MESA	Yes	68	4 (4, 4)	9 (9, 10)	8	1.41	0.99 (0.49, 1.98)	0.88 (0.44, 1.78)	-1.53 (2.37)	0.51 (-0.09, 1.10)
	No	3,660	4 (4, 4)	9 (9, 10)	447	1.39	<i>reference</i>	<i>reference</i>	-1.70 (2.45)	<i>reference</i>
Meta-Analysis	Yes	503	3 (2,3)	8 (8, 8)	115	2.17	1.26 (1.03, 1.63)	1.27 (1.04, 1.54)	-1.69 (1.66)	0.03 (-0.43, 0.50)
	No	11,501	3 (2,3)	8 (8, 8)	2,131	1.72	<i>reference</i>	<i>reference</i>	-1.67 (1.68)	<i>reference</i>
							p = 0.026	p = 0.018		p = 0.884

ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate. *Adjusted for age, age-squared, sex, baseline eGFR, diabetes, and log-urine albumin to creatinine ratio (where available at baseline). †Adjusted for age, age-squared, sex, diabetes and log-urine albumin to creatinine ratio (where available at baseline)

Table S6. Associations of Clonal Hematopoiesis with 30% decline in eGFR and longitudinal change in eGFR among individuals with eGFR<60 at baseline

Study	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	30% decline in eGFR				Percent eGFR decline per year	
					Number of events	Incidence per 100 p-y	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)	Mean (SD)	Adjusted† difference (95% CI)
ARIC	Yes	11	3 (2,3)	9 (3,9)	1	1.19	0.36 (0.05, 2.79)	0.38 (0.05, 3.02)	-3.73 (3.98)	0.53 (-7.74, 8.82)
	No	60	3 (2,3)	8 (3,9)	13	3.16	<i>reference</i>	<i>reference</i>	-3.59 (11.1)	<i>reference</i>
CHS	Yes	71	3 (2,3)	7 (3,7)	11	2.50	1.62 (0.84, 3.14)	1.53 (0.71, 3.28)	-1.10 (3.83)	-0.03 (-0.75, 0.67)
	No	379	3 (2,3)	7 (3,7)	46	1.80	<i>reference</i>	<i>reference</i>	-0.84 (4.01)	<i>reference</i>
MESA	Yes	27	4 (3, 4)	9 (4, 9)	3	1.60	0.77 (0.24, 2.48)	0.75 (0.23, 2.45)	-1.74 (4.27)	0.60 (-1.01, 2.21)
	No	325	4 (3, 4)	9 (9, 10)	62	2.31	<i>reference</i>	<i>reference</i>	-1.89 (4.00)	<i>reference</i>
Meta-Analysis	Yes	109	3 (2,3)	8 (8, 8)	15	2.15	1.07 (0.50, 2.30)	1.06 (0.52, 2.13)	-2.18 (2.32)	0.34 (-0.12, 0.79)
	No	764	3 (2,3)	8 (8, 8)	121	2.12	<i>reference</i>	<i>reference</i>	-1.50 (2.74)	<i>reference</i>
							p = 0.852	p = 0.872		p = 0.150

ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate. *Adjusted for age, age-squared, sex, baseline eGFR, diabetes, and log-urine albumin to creatinine ratio (where available at baseline). †Adjusted for age, age-squared, sex, diabetes and log-urine albumin to creatinine ratio (where available at baseline)

Table S7. Associations of Clonal Hematopoiesis with 30% decline in eGFR and longitudinal change in eGFR among individuals with diabetes at baseline

Study	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	30% decline in eGFR				Percent eGFR decline per year	
					Number of events	Incidence per 100 p-y	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)	Mean (SD)	Adjusted† difference (95% CI)
ARIC	Yes	64	3 (3,3)	9 (3,9)	16	3.43	1.36 (0.81, 2.29)	1.26 (0.74, 2.14)	-4.31 (5.02)	-1.21 (-2.71, 0.29)
	No	650	3 (2,3)	9 (3,9)	160	2.90	<i>reference</i>	<i>reference</i>	-3.03 (5.05)	<i>reference</i>
CHS	Yes	33	3 (2,3)	6 (3,7)	8	3.89	1.72 (0.76, 3.89)	1.26 (0.44, 3.59)	-2.08 (5.29)	0.49 (-1.59, 2.57)
	No	222	3 (2,3)	7 (3,7)	37	2.54	<i>reference</i>	<i>reference</i>	-1.71 (5.39)	<i>reference</i>
MESA	Yes	22	4 (3, 4)	9 (9, 10)	2	1.18	0.34 (0.08, 1.37)	0.28 (0.07, 1.16)	-2.28 (4.35)	1.42 (-0.13, 2.98)
	No	428	4 (4, 4)	9 (9, 10)	138	3.91	<i>reference</i>	<i>reference</i>	-3.09 (3.63)	<i>reference</i>
Meta-Analysis	Yes	119	3 (2,3)	8 (8, 8)	26	3.14	1.28 (0.84, 1.95)	0.93 (0.44, 1.96)	-2.85 (2.79)	0.20 (-1.42, 1.83)
	No	1,300	3 (2,3)	8 (8, 8)	335	3.17	<i>reference</i>	<i>reference</i>	-2.76 (2.59)	<i>reference</i>
							p = 0.244	p = 0.856	p = 0.807	
ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate. *Adjusted for age, age-squared, sex, baseline eGFR, diabetes and log-urine albumin to creatinine ratio (where available at baseline). †Adjusted for age, age-squared, sex, diabetes and log-urine albumin to creatinine ratio (where available at baseline)										

Table S8. Associations of Clonal Hematopoiesis with 30% decline in eGFR and longitudinal change in eGFR among individuals without diabetes at baseline

Study	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	30% decline in eGFR				Percent eGFR decline per year	
					Number of events	Incidence per 100 p-y	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)	Mean (SD)	Adjusted† difference (95% CI)
ARIC	Yes	520	3 (3,4)	9 (8,23)	127	2.10	1.22 (1.02, 1.47)	1.19 (0.99, 1.44)	-2.06 (2.65)	-0.17 (-0.39, 0.05)
	No	5341	3 (3,4)	9 (9,23)	1,232	1.86	<i>reference</i>	<i>reference</i>	-1.90 (2.35)	<i>reference</i>
CHS	Yes	207	3 (2,3)	7 (3,7)	32	1.93	1.49 (0.99, 2.24)	1.35 (0.87, 2.12)	-0.81 (4.48)	-0.21 (-0.72, 0.31)
	No	1239	3 (2,3)	7 (4,13)	179	1.36	<i>reference</i>	<i>reference</i>	-0.69 (3.54)	<i>reference</i>
MESA	Yes	156	4 (4, 4)	9 (9, 10)	20	1.48	1.28 (0.81, 2.02)	1.07 (0.68, 1.68)	-1.50 (2.25)	0.21 (-0.14, 0.57)
	No	3122	4 (4, 4)	9 (9, 10)	295	1.07	<i>reference</i>	<i>reference</i>	-1.52 (2.17)	<i>reference</i>
Meta-Analysis	Yes	883	3 (2,3)	8 (8, 8)	179	1.19	1.26 (1.08, 1.48)	1.19 (1.02, 1.40)	-1.62 (1.60)	-0.06 (-0.32, 0.21)
	No	9,702	3 (2,3)	8 (8, 8)	1,706	1.08	<i>reference</i>	<i>reference</i>	-1.52 (1.45)	<i>reference</i>
							p = 0.003	p = 0.032	p = 0.671	
ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate. *Adjusted for age, age-squared, sex, baseline eGFR, diabetes and log-urine albumin to creatinine ratio (where available at baseline). †Adjusted for age, age-squared, sex, diabetes and log-urine albumin to creatinine ratio (where available at baseline)										

Table S9. Associations of Clonal Hematopoiesis with 30% decline in eGFR and longitudinal change in eGFR among individuals aged > 60 years at baseline

Study	CHIP	Number of participants	Number of eGFRs	Median follow-up time, years (IQR)	30% decline in eGFR				Percent eGFR decline per year	
					Number of events	Incidence per 100 p-y	Unadjusted HR (95% CI)	Adjusted* HR (95%CI)	Mean (SD)	Adjusted† difference (95% CI)
ARIC	Yes	209	3 (3,3)	9 (9,9)	47	2.37	1.16 (0.86, 1.58)	1.15 (0.84, 1.56)	-2.66 (3.56)	-0.35 (-0.84, 0.13)
	No	1583	3 (3,3)	9 (8,9)	321	2.09	<i>reference</i>	<i>reference</i>	-2.34 (3.11)	<i>reference</i>
CHS	Yes	238	3 (2,3)	7 (3,7)	35	2.14	1.48 (1.02,2.13)	1.38 (0.92, 2.06)	-0.98 (4.60)	-0.15 (-0.68, 0.38)
	No	1,441	3 (2,3)	7 (4,8)	163	1.53	<i>reference</i>	<i>reference</i>	-0.85 (3.89)	<i>reference</i>
MESA	Yes	138	4 (3, 4)	9 (8, 10)	20	1.76	0.97 (0.62, 1.53)	0.93 (0.59, 1.46)	-1.73 (2.85)	0.43 (-0.03, 0.89)
	No	2151	4 (4, 4)	9 (9, 10)	323	1.78	<i>reference</i>	<i>reference</i>	-1.94 (2.65)	<i>reference</i>
Meta-Analysis	Yes	585	3 (2,3)	8 (8, 8)	102	2.13	1.21 (0.98, 1.49)	1.15 (0.93, 1.43)	-1.88 (2.00)	-0.01 (-0.49, 0.46)
	No	5,175	3 (2,3)	8 (8, 8)	807	1.81	<i>reference</i>	<i>reference</i>	-1.84 (1.79)	<i>reference</i>
							p = 0.076	p = 0.191	p = 0.950	
ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate. *Adjusted for age, age-squared, sex, baseline eGFR, diabetes and log-urine albumin to creatinine ratio (where available at baseline). †Adjusted for age, age-squared, sex, diabetes and log-urine albumin to creatinine ratio (where available at baseline)										